| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 7 | 2023 | 393 | 2.600 |
Why?
|
| Students | 8 | 2022 | 198 | 2.030 |
Why?
|
| Sex Offenses | 8 | 2018 | 38 | 1.770 |
Why?
|
| Pregnancy | 21 | 2022 | 2143 | 1.640 |
Why?
|
| Contraception | 4 | 2017 | 61 | 1.620 |
Why?
|
| Sexually Transmitted Diseases | 7 | 2018 | 90 | 1.580 |
Why?
|
| Intimate Partner Violence | 5 | 2018 | 25 | 1.580 |
Why?
|
| Female | 55 | 2023 | 26612 | 1.510 |
Why?
|
| Humans | 76 | 2023 | 50636 | 1.460 |
Why?
|
| Contraception Behavior | 4 | 2014 | 34 | 1.360 |
Why?
|
| Adolescent Behavior | 5 | 2018 | 176 | 1.360 |
Why?
|
| Universities | 10 | 2022 | 139 | 1.320 |
Why?
|
| Safe Sex | 4 | 2018 | 24 | 1.310 |
Why?
|
| Sexual Behavior | 7 | 2015 | 196 | 1.290 |
Why?
|
| Alcohol Drinking | 4 | 2018 | 271 | 1.270 |
Why?
|
| Papillomavirus Infections | 6 | 2016 | 141 | 1.250 |
Why?
|
| Spouse Abuse | 5 | 2014 | 42 | 1.170 |
Why?
|
| Reproductive Health | 3 | 2022 | 23 | 1.140 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 389 | 1.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2023 | 712 | 1.140 |
Why?
|
| Social Justice | 2 | 2023 | 29 | 1.120 |
Why?
|
| Mass Screening | 7 | 2020 | 548 | 1.090 |
Why?
|
| Benzimidazoles | 2 | 2016 | 50 | 1.080 |
Why?
|
| Papillomavirus Vaccines | 6 | 2016 | 69 | 1.030 |
Why?
|
| Decision Making | 5 | 2018 | 339 | 1.010 |
Why?
|
| Health Promotion | 2 | 2023 | 487 | 1.000 |
Why?
|
| Sexual Partners | 6 | 2019 | 96 | 0.960 |
Why?
|
| Fructose | 2 | 2014 | 35 | 0.950 |
Why?
|
| Pregnancy in Adolescence | 2 | 2015 | 23 | 0.940 |
Why?
|
| Women's Rights | 1 | 2023 | 6 | 0.930 |
Why?
|
| Endometriosis | 2 | 2020 | 19 | 0.920 |
Why?
|
| United States | 19 | 2020 | 6433 | 0.920 |
Why?
|
| Nurses | 1 | 2023 | 84 | 0.900 |
Why?
|
| Adolescent | 23 | 2018 | 5331 | 0.890 |
Why?
|
| Mentoring | 1 | 2022 | 32 | 0.860 |
Why?
|
| Vaccines | 1 | 2023 | 90 | 0.860 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2019 | 30 | 0.850 |
Why?
|
| Mentors | 1 | 2022 | 108 | 0.840 |
Why?
|
| Nursing Research | 3 | 2017 | 36 | 0.830 |
Why?
|
| Communication | 4 | 2022 | 475 | 0.820 |
Why?
|
| Publishing | 1 | 2022 | 83 | 0.820 |
Why?
|
| Antiviral Agents | 2 | 2015 | 300 | 0.800 |
Why?
|
| Rape | 2 | 2011 | 13 | 0.800 |
Why?
|
| Public Health | 2 | 2022 | 157 | 0.780 |
Why?
|
| Nasal Sprays | 1 | 2020 | 2 | 0.780 |
Why?
|
| Benzaldehydes | 1 | 2020 | 2 | 0.780 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2020 | 6 | 0.770 |
Why?
|
| Adult | 26 | 2020 | 13417 | 0.760 |
Why?
|
| Ketamine | 1 | 2020 | 18 | 0.760 |
Why?
|
| Nurse Practitioners | 4 | 2020 | 112 | 0.760 |
Why?
|
| Pyrazines | 1 | 2020 | 31 | 0.760 |
Why?
|
| Focus Groups | 4 | 2017 | 257 | 0.750 |
Why?
|
| Depression, Postpartum | 2 | 2019 | 143 | 0.750 |
Why?
|
| Pain | 4 | 2020 | 317 | 0.750 |
Why?
|
| Social Media | 1 | 2022 | 114 | 0.740 |
Why?
|
| Pyrazoles | 1 | 2020 | 64 | 0.740 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 61 | 0.730 |
Why?
|
| Dyspareunia | 3 | 2020 | 7 | 0.730 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2019 | 9 | 0.730 |
Why?
|
| beta-Cyclodextrins | 1 | 2019 | 24 | 0.720 |
Why?
|
| Pregnanolone | 1 | 2019 | 24 | 0.720 |
Why?
|
| Pyrimidines | 1 | 2019 | 105 | 0.690 |
Why?
|
| Abdominal Pain | 1 | 2019 | 83 | 0.690 |
Why?
|
| Counterfeit Drugs | 1 | 2018 | 1 | 0.680 |
Why?
|
| Risk-Taking | 3 | 2014 | 155 | 0.680 |
Why?
|
| Self Report | 3 | 2017 | 324 | 0.670 |
Why?
|
| Violence | 3 | 2014 | 153 | 0.650 |
Why?
|
| Young Adult | 17 | 2018 | 3731 | 0.640 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 135 | 0.640 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 11 | 0.640 |
Why?
|
| Dronabinol | 1 | 2017 | 28 | 0.620 |
Why?
|
| Ovary | 1 | 2017 | 110 | 0.610 |
Why?
|
| Tobacco Use | 1 | 2017 | 30 | 0.610 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 77 | 0.600 |
Why?
|
| Cannabis | 1 | 2017 | 37 | 0.600 |
Why?
|
| Obesity | 2 | 2016 | 1139 | 0.600 |
Why?
|
| Aspirin | 1 | 2018 | 164 | 0.590 |
Why?
|
| Libido | 1 | 2016 | 3 | 0.590 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2015 | 151 | 0.590 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2016 | 10 | 0.590 |
Why?
|
| Mothers | 1 | 2019 | 241 | 0.580 |
Why?
|
| Vascular Diseases | 1 | 2016 | 52 | 0.580 |
Why?
|
| Sex Education | 2 | 2018 | 24 | 0.580 |
Why?
|
| Phytotherapy | 1 | 2016 | 53 | 0.570 |
Why?
|
| Infertility | 1 | 2016 | 34 | 0.570 |
Why?
|
| Sexuality | 2 | 2012 | 21 | 0.550 |
Why?
|
| Hot Flashes | 1 | 2016 | 88 | 0.550 |
Why?
|
| Intrauterine Devices | 1 | 2015 | 5 | 0.550 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 8 | 0.540 |
Why?
|
| Drug Labeling | 1 | 2015 | 29 | 0.540 |
Why?
|
| Fluorenes | 1 | 2015 | 11 | 0.540 |
Why?
|
| Ambulatory Care | 1 | 2017 | 264 | 0.540 |
Why?
|
| Domestic Violence | 2 | 2012 | 35 | 0.540 |
Why?
|
| Lactation | 1 | 2015 | 68 | 0.530 |
Why?
|
| New England | 6 | 2018 | 242 | 0.530 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 81 | 0.530 |
Why?
|
| Prescription Drugs | 1 | 2015 | 49 | 0.520 |
Why?
|
| Negotiating | 1 | 2014 | 14 | 0.520 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 350 | 0.520 |
Why?
|
| Vulva | 1 | 2014 | 16 | 0.510 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 15 | 0.510 |
Why?
|
| Migraine Disorders | 1 | 2014 | 39 | 0.510 |
Why?
|
| Tamoxifen | 1 | 2014 | 34 | 0.510 |
Why?
|
| Dicyclomine | 1 | 2014 | 1 | 0.500 |
Why?
|
| Doxylamine | 1 | 2014 | 1 | 0.500 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2014 | 1 | 0.500 |
Why?
|
| Pyridoxine | 1 | 2014 | 4 | 0.500 |
Why?
|
| Morning Sickness | 1 | 2014 | 3 | 0.500 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 55 | 0.500 |
Why?
|
| Menopause | 1 | 2016 | 236 | 0.500 |
Why?
|
| Vagina | 1 | 2014 | 81 | 0.500 |
Why?
|
| Antiemetics | 1 | 2014 | 21 | 0.490 |
Why?
|
| Research Design | 1 | 2017 | 547 | 0.490 |
Why?
|
| Disclosure | 1 | 2014 | 44 | 0.480 |
Why?
|
| Ceftriaxone | 1 | 2013 | 17 | 0.480 |
Why?
|
| Phentermine | 1 | 2013 | 2 | 0.470 |
Why?
|
| Hepatitis C | 1 | 2015 | 127 | 0.470 |
Why?
|
| Pregnancy, High-Risk | 2 | 2012 | 20 | 0.470 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 10 | 0.470 |
Why?
|
| Benzazepines | 1 | 2013 | 22 | 0.460 |
Why?
|
| Condylomata Acuminata | 1 | 2012 | 13 | 0.460 |
Why?
|
| Catechin | 1 | 2012 | 32 | 0.440 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 616 | 0.440 |
Why?
|
| Family Planning Services | 2 | 2012 | 22 | 0.440 |
Why?
|
| Battered Women | 1 | 2012 | 12 | 0.440 |
Why?
|
| Health Surveys | 3 | 2014 | 303 | 0.440 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 449 | 0.430 |
Why?
|
| Women | 2 | 2014 | 43 | 0.430 |
Why?
|
| Drug Combinations | 3 | 2019 | 121 | 0.420 |
Why?
|
| Progesterone | 1 | 2012 | 153 | 0.410 |
Why?
|
| Feminism | 1 | 2011 | 1 | 0.410 |
Why?
|
| Social Control, Formal | 1 | 2011 | 16 | 0.400 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 35 | 0.400 |
Why?
|
| Psychiatric Nursing | 1 | 2010 | 11 | 0.400 |
Why?
|
| Infant, Newborn | 3 | 2020 | 1196 | 0.400 |
Why?
|
| Drug Resistance, Multiple | 1 | 2010 | 32 | 0.390 |
Why?
|
| Insulin | 1 | 2015 | 658 | 0.390 |
Why?
|
| Gonorrhea | 1 | 2013 | 195 | 0.390 |
Why?
|
| Hospitals, Psychiatric | 1 | 2010 | 48 | 0.390 |
Why?
|
| Premature Birth | 1 | 2012 | 108 | 0.390 |
Why?
|
| Time Factors | 1 | 2017 | 3161 | 0.380 |
Why?
|
| Quality of Life | 2 | 2020 | 782 | 0.380 |
Why?
|
| Postpartum Period | 3 | 2020 | 174 | 0.370 |
Why?
|
| Patient Selection | 1 | 2012 | 352 | 0.370 |
Why?
|
| Cross Infection | 1 | 2010 | 130 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 588 | 0.360 |
Why?
|
| Nurse's Role | 3 | 2023 | 110 | 0.360 |
Why?
|
| Intrauterine Devices, Copper | 1 | 2008 | 2 | 0.340 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2008 | 6 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 590 | 0.330 |
Why?
|
| Forensic Nursing | 3 | 2012 | 3 | 0.330 |
Why?
|
| Vaccination | 2 | 2023 | 301 | 0.320 |
Why?
|
| Methadone | 2 | 2019 | 94 | 0.310 |
Why?
|
| Risk Factors | 9 | 2022 | 4352 | 0.300 |
Why?
|
| Risk Reduction Behavior | 3 | 2018 | 126 | 0.290 |
Why?
|
| HIV Infections | 4 | 2020 | 902 | 0.280 |
Why?
|
| Pediatric Nursing | 2 | 2017 | 11 | 0.280 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 84 | 0.270 |
Why?
|
| Buprenorphine | 2 | 2019 | 146 | 0.270 |
Why?
|
| Drug Interactions | 2 | 2016 | 104 | 0.270 |
Why?
|
| Male | 14 | 2020 | 23332 | 0.260 |
Why?
|
| Risk | 2 | 2018 | 358 | 0.260 |
Why?
|
| Administration, Oral | 2 | 2016 | 304 | 0.250 |
Why?
|
| Nurse-Patient Relations | 2 | 2018 | 39 | 0.240 |
Why?
|
| Urban Population | 2 | 2016 | 185 | 0.240 |
Why?
|
| Needs Assessment | 2 | 2017 | 160 | 0.230 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 375 | 0.230 |
Why?
|
| Life Style | 2 | 2016 | 311 | 0.230 |
Why?
|
| Cultural Diversity | 1 | 2023 | 36 | 0.230 |
Why?
|
| Fathers | 2 | 2019 | 25 | 0.220 |
Why?
|
| Emergency Nursing | 2 | 2012 | 16 | 0.220 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 2196 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2018 | 1596 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3952 | 0.220 |
Why?
|
| Child | 4 | 2020 | 3870 | 0.220 |
Why?
|
| Food Supply | 1 | 2022 | 69 | 0.210 |
Why?
|
| Crime | 1 | 2012 | 52 | 0.210 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2293 | 0.210 |
Why?
|
| Heroin | 1 | 2020 | 11 | 0.200 |
Why?
|
| Hematologic Agents | 1 | 2020 | 3 | 0.190 |
Why?
|
| Outpatients | 1 | 2020 | 119 | 0.190 |
Why?
|
| Courtship | 2 | 2011 | 5 | 0.190 |
Why?
|
| Hormone Antagonists | 1 | 2019 | 10 | 0.180 |
Why?
|
| Dysmenorrhea | 1 | 2019 | 8 | 0.180 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 48 | 0.180 |
Why?
|
| Middle Aged | 8 | 2019 | 13532 | 0.180 |
Why?
|
| Morphine | 1 | 2019 | 52 | 0.180 |
Why?
|
| Drug Therapy | 1 | 2019 | 56 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 420 | 0.170 |
Why?
|
| Sexual Harassment | 1 | 2018 | 12 | 0.170 |
Why?
|
| Pharmaceutical Services, Online | 1 | 2018 | 1 | 0.170 |
Why?
|
| Organizational Policy | 1 | 2018 | 53 | 0.170 |
Why?
|
| Papillomaviridae | 2 | 2015 | 56 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2012 | 774 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 357 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 212 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 45 | 0.170 |
Why?
|
| Hysteroscopy | 1 | 2017 | 3 | 0.160 |
Why?
|
| Nursing Process | 1 | 2017 | 5 | 0.160 |
Why?
|
| Dizziness | 1 | 2017 | 17 | 0.160 |
Why?
|
| Nausea | 1 | 2017 | 34 | 0.160 |
Why?
|
| Prevalence | 3 | 2017 | 1130 | 0.160 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2016 | 15 | 0.150 |
Why?
|
| Paroxetine | 1 | 2016 | 14 | 0.150 |
Why?
|
| Anovulation | 1 | 2016 | 8 | 0.150 |
Why?
|
| Homosexuality, Male | 1 | 2016 | 54 | 0.150 |
Why?
|
| Serotonin Agents | 1 | 2016 | 11 | 0.150 |
Why?
|
| Contraindications | 1 | 2016 | 33 | 0.150 |
Why?
|
| Syncope | 1 | 2016 | 23 | 0.150 |
Why?
|
| Hypotension | 1 | 2016 | 36 | 0.140 |
Why?
|
| Drug Approval | 1 | 2016 | 26 | 0.140 |
Why?
|
| Premenopause | 1 | 2016 | 54 | 0.140 |
Why?
|
| Infant | 1 | 2020 | 1415 | 0.140 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 34 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2020 | 486 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 156 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2015 | 15 | 0.140 |
Why?
|
| Pregnancy Rate | 1 | 2015 | 34 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2016 | 161 | 0.130 |
Why?
|
| Pregnancy, Unwanted | 1 | 2014 | 10 | 0.130 |
Why?
|
| Coercion | 1 | 2015 | 39 | 0.130 |
Why?
|
| Interviews as Topic | 2 | 2019 | 418 | 0.130 |
Why?
|
| Atrophy | 1 | 2014 | 47 | 0.130 |
Why?
|
| Obstetric Nursing | 1 | 2014 | 1 | 0.130 |
Why?
|
| Drug Information Services | 1 | 2014 | 5 | 0.130 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 9 | 0.130 |
Why?
|
| Dissociative Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2014 | 21 | 0.120 |
Why?
|
| Rural Population | 2 | 2012 | 166 | 0.120 |
Why?
|
| Health Education | 1 | 2015 | 192 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2016 | 317 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2015 | 128 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 247 | 0.120 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 139 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 99 | 0.120 |
Why?
|
| Ethanol | 1 | 2016 | 263 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 20 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 68 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 192 | 0.110 |
Why?
|
| Administration, Topical | 1 | 2012 | 43 | 0.110 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 16 | 0.110 |
Why?
|
| Social Identification | 1 | 2012 | 14 | 0.110 |
Why?
|
| Perception | 1 | 2014 | 165 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 75 | 0.110 |
Why?
|
| Administration, Intravaginal | 1 | 2012 | 9 | 0.110 |
Why?
|
| Contraception, Postcoital | 1 | 2012 | 4 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2014 | 4746 | 0.110 |
Why?
|
| Physical Examination | 1 | 2012 | 95 | 0.110 |
Why?
|
| Child Abuse, Sexual | 1 | 2011 | 23 | 0.110 |
Why?
|
| Liver | 1 | 2016 | 707 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 369 | 0.100 |
Why?
|
| Breast Feeding | 1 | 2013 | 128 | 0.100 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2011 | 25 | 0.100 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 1 | 2010 | 1 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 722 | 0.100 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 185 | 0.100 |
Why?
|
| Crime Victims | 1 | 2011 | 39 | 0.100 |
Why?
|
| Social Behavior | 1 | 2011 | 80 | 0.100 |
Why?
|
| Motivation | 1 | 2012 | 243 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2010 | 262 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 532 | 0.090 |
Why?
|
| Exercise | 1 | 2016 | 823 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 510 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 863 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 492 | 0.090 |
Why?
|
| Intrauterine Device Expulsion | 1 | 2008 | 1 | 0.080 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2008 | 25 | 0.080 |
Why?
|
| Uterine Hemorrhage | 1 | 2008 | 20 | 0.080 |
Why?
|
| North America | 1 | 2008 | 104 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2008 | 43 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 639 | 0.080 |
Why?
|
| Parity | 1 | 2008 | 71 | 0.080 |
Why?
|
| Safety | 1 | 2008 | 127 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 201 | 0.070 |
Why?
|
| Condoms | 2 | 2018 | 47 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 295 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 620 | 0.070 |
Why?
|
| Counseling | 1 | 2008 | 392 | 0.070 |
Why?
|
| Logistic Models | 2 | 2014 | 1160 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 815 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 446 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2012 | 139 | 0.050 |
Why?
|
| Internet | 2 | 2015 | 464 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 759 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2012 | 201 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 233 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 831 | 0.050 |
Why?
|
| Sex Factors | 1 | 2012 | 853 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 103 | 0.040 |
Why?
|
| Father-Child Relations | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nuclear Family | 1 | 2018 | 18 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2012 | 383 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2015 | 10 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2015 | 254 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2014 | 28 | 0.030 |
Why?
|
| Age Distribution | 1 | 2012 | 234 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2012 | 63 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2011 | 26 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1128 | 0.030 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2011 | 4 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2011 | 358 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 295 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1314 | 0.020 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Psychology, Adolescent | 1 | 2007 | 25 | 0.020 |
Why?
|
| Massachusetts | 1 | 2012 | 1997 | 0.020 |
Why?
|
| Aged | 1 | 2012 | 10999 | 0.010 |
Why?
|